美股市场个股详情

BPMC Blueprint Medicines

添加自选

91.340
-1.760-1.89%

收盘价 04/30 16:00 (美东)

91.340
0.0000.00%

盘后 17:11 (美东)

57.38亿总市值-10912市盈率TTM

Blueprint Medicines股票讨论区

登录发表评论

Stock_Drift

04/12 09:13

Extended Hours Top Moovers.

$Gryphon Digital Mining(GRYP.US)$$齐默巴奥米特控股(ZBH.US)$$科休半导体(COHU.US)$$Evolv Technologies(EVLV.US)$$Brookfield(BN.US)$ $VACASA INC(VCSA.US)$$Blueprint Medicines(BPMC.US)$$Williams-Sonoma(WSM.US)$$美国世纪银行(USCB.US)$
📊⚡️📊

frankinglily

04/01 16:50

Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:

$SPDR标普生物科技ETF(XBI.US)$
$默沙东(MRK.US)$ x $Immunovant(IMVT.US)$
$礼来(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$再生元制药公司(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$吉利德科学(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$施贵宝(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$礼来(LLY.US)$ x $Merus(MRUS.US)$ (partner n...

Moomoo AI

03/15 19:44

Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.

Possible Bearish Signals With Blueprint Medicines Insiders Disposing Stock

Moomoo AI

02/20 02:10

The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.

Blueprint Medicines (NASDAQ:BPMC) Delivers Shareholders Decent 95% Return Over 1 Year, Surging 16% in the Last Week Alone

Moomoo AI

01/29 23:59

Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.

Blueprint Medicines Corporation's (NASDAQ:BPMC) Shareholders Might Be Looking For Exit

Moomoo AI

2023/12/18 22:23

Blueprint Medicines' increased debt brings a heightened risk profile due to last year's dilution in revenues and lack of profitability. Its future earnings and balance sheet health are key to assessing risk.

Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

淡定的惠特莫爾

2023/11/22 03:06

美国东部时间11月10日上午8点10分，“Blueprint Medicines获得CHMP对艾瓦基特的正面评价

$3倍做多生物技术ETF-Direxion(LABU.US)$

Moomoo AI

2023/11/14 20:44

Significant sale by President of R&D Fouad Namouni implies shares may not be undervalued. This, along with multiple insider sales, is a potential red flag for investors.

Blueprint Medicines Insiders Sold US$2.1m Of Shares Suggesting Hesitancy

Moomoo AI

2023/10/17 21:11

The significant fall in both the share price and revenue of Blueprint Medicines Corporation could indicate unresolved issues within the company. The continued lack of profitability may also be a concern for long-term investors.

Loss-making Blueprint Medicines (NASDAQ:BPMC) Sheds a Further US$118m, Taking Total Shareholder Losses to 53% Over 3 Years

Analysts Notebook

2022/07/08 19:47

专栏Top upgrades and downgrades on 7/8: PYPL, UPST, AAL, RCKT and more

Upgrades
• $Vita Coco(COCO.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $12 (from $10)
• $Diebold Nixdorf(DBD.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $5
• $Eversource Energy(ES.US)$ : Guggenheim Upgrades to Buy from Neutral - PT $97 (from $92)
• $Howmet Aerospace(HWM.US)$ : Benchmark Upgrades to Buy from Neutral - PT $40
• $埃培智(IPG.US)$ : Wells Fargo Upgrades to Overweight...

暂无评论

分析

分析师评级

暂无数据

目标价预测

暂无数据

热议

美股

综合热度

所属概念

抗癌医药

今日-0.53%